

# CITATION REPORT

List of articles citing

Acute blood loss stimulates fibroblast growth factor 23 production

DOI: 10.1152/ajprenal.00081.2017

American Journal of Physiology - Renal Physiology,  
2018, 314, F132-F139.

**Source:** <https://exaly.com/paper-pdf/69637736/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
47	Non-renal-Related Mechanisms of FGF23 Pathophysiology. <i>Current Osteoporosis Reports</i> , <b>2018</b> , 16, 724-734	3.9	16
46	Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2018</b> , 470, 1569-1582	4.6	50
45	Phosphate homeostasis disorders. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 32, 685-706	6.5	40
44	Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34, 2057-2065	4.3	58
43	Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011130	6	8
42	Elevated FGF23 and disordered renal mineral handling with reduced bone mineralization in chronically erythropoietin over-expressing transgenic mice. <i>Scientific Reports</i> , <b>2019</b> , 9, 14989	4.9	6
41	Plasma total fibroblast growth factor 23 levels are associated with acute kidney injury and mortality in children with acute respiratory distress syndrome. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222065	3.7	2
40	Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. <i>Kidney International</i> , <b>2019</b> , 96, 1346-1358	9.9	29
39	The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	37
38	The FGF metabolic axis. <i>Frontiers of Medicine</i> , <b>2019</b> , 13, 511-530	12	54
37	Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. <i>Kidney International Reports</i> , <b>2019</b> , 4, 1742-1748	4.1	4
36	FGF23 Synthesis and Activity. <i>Current Molecular Biology Reports</i> , <b>2019</b> , 5, 18-25	2	8
35	Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002818	11.6	8
34	Regulation of fibroblast growth factor 23 (FGF23) in health and disease. <i>FEBS Letters</i> , <b>2019</b> , 593, 1879-1900	3.0	37
33	Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. <i>Current Molecular Biology Reports</i> , <b>2019</b> , 5, 8-17	2	17
32	FGF23, Biomarker or Target?. <i>Toxins</i> , <b>2019</b> , 11,	4.9	23
31	The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research. <i>Frontiers in Physiology</i> , <b>2019</b> , 10, 304	4.6	21

30	Hypoxia Signaling in the Skeleton: Implications for Bone Health. <i>Current Osteoporosis Reports</i> , <b>2019</b> , 17, 26-35	5.4	26
29	Hypoxia, hypoxia-inducible transcription factors and oxygen-sensing prolyl hydroxylases in bone development and homeostasis. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2019</b> , 28, 328-335	3.5	11
28	Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2019</b> , 28, 304-310	3.5	10
27	FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. <i>Nature Reviews Nephrology</i> , <b>2020</b> , 16, 7-19	14.9	93
26	High Plasma Erythropoietin Predicts Incident Fractures in Elderly Men with Normal Renal Function: The MrOS Sweden Cohort. <i>Journal of Bone and Mineral Research</i> , <b>2020</b> , 35, 298-305	6.3	11
25	Extra-Large GIProtein (XL $\beta$ ) Deficiency Causes Severe Adenine-Induced Renal Injury with Massive FGF23 Elevation. <i>Endocrinology</i> , <b>2020</b> , 161,	4.8	1
24	Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. <i>Blood Advances</i> , <b>2020</b> , 4, 1678-1682	7.8	6
23	Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2020</b> , 29, 359-366	3.5	2
22	Erythropoietin, Fibroblast Growth Factor 23, and Death After Kidney Transplantation. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	
21	Low doses of recombinant human erythropoietin does not affect C-terminal FGF23 in healthy men. <i>Drug Testing and Analysis</i> , <b>2020</b> , 12, 975-979	3.5	2
20	Tumor-Induced Osteomalacia. <i>Calcified Tissue International</i> , <b>2021</b> , 108, 128-142	3.9	46
19	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> , 36, 315-321	6.3	3
18	FGF23 and kidney disease. <b>2021</b> , 115-131		
17	Upstream Regulators of Fibroblast Growth Factor 23. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 588096	5.7	6
16	Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients. <i>Pediatric Nephrology</i> , <b>2021</b> , 36, 3241-3249	3.2	0
15	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , <b>2021</b> , 99, 1280-1295	9.9	18
14	Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone. <i>Kidney International</i> , <b>2021</b> , 100, 79-89	9.9	7
13	Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review). <i>Experimental and Therapeutic Medicine</i> , <b>2021</b> , 22, 1159	2.1	0

12	Challenges in the management of tumor-induced osteomalacia (TIO). <i>Bone</i> , <b>2021</b> , 152, 116064	4.7	6
11	The regulation of FGF23 production in bone and outside of bone. <b>2021</b> , 31-51		
10	FGF23 and inflammation, anemia, and iron. <b>2021</b> , 157-174		
9	Systemic Jak1 activation provokes hepatic inflammation and imbalanced FGF23 production and cleavage. <i>FASEB Journal</i> , <b>2021</b> , 35, e21302	0.9	5
8	Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 1513-1526	15.9	36
7	Selective pharmacological inhibition of the sodium-dependent phosphate cotransporter NPT2a promotes phosphate excretion. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 6510-6522	15.9	7
6	Role of fibroblast growth factor 23 in patients with chronic kidney disease. <i>Chinese Medical Journal</i> , <b>2020</b> , 134, 404-406	2.9	1
5	Interconnections of fibroblast growth factor 23 and klotho with erythropoietin and hypoxia-inducible factor.. <i>Molecular and Cellular Biochemistry</i> , <b>2022</b> ,	4.2	
4	Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease.. <i>Scientific Reports</i> , <b>2022</b> , 12, 6695	4.9	
3	Lipocalin-2: a novel link between the injured kidney and the bone. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2022</b> , 31, 312-319	3.5	0
2	Dual Role of Fibroblast Growth Factor Pathways in Sleep Regulation.. <b>2022</b> , 22,		1
1	FGF23 tumor induced osteomalacia. <b>2022</b> , 68, 56-66		0